GRAIL, Inc.
GRAIL, Inc., a pioneering company in the field of early cancer detection, is headquartered in the United States. Founded in 2016, GRAIL has rapidly established itself as a leader in the biotechnology industry, focusing on innovative blood tests that aim to identify multiple types of cancer at their earliest stages. With a commitment to transforming cancer care, GRAIL's flagship product, Galleri™, utilises advanced genomic sequencing technology to detect cancer signals in the bloodstream, setting it apart from traditional screening methods. The company has achieved significant milestones, including partnerships with major healthcare providers and research institutions, enhancing its market position. GRAIL continues to push the boundaries of cancer diagnostics, striving to improve patient outcomes and revolutionise the way cancer is detected and treated.
DitchCarbon Score
How does GRAIL, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GRAIL, Inc.'s score of 28 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GRAIL, Inc.'s reported carbon emissions
GRAIL, Inc., headquartered in the United States, is committed to achieving net-zero carbon emissions across all scopes by 2050. As of now, there is no available data on their carbon emissions in kg CO2e. However, the company has made significant commitments to address climate change, including a long-term target for net-zero emissions, which is aligned with the Science Based Targets initiative (SBTi). GRAIL is actively working towards these goals, having established a commitment to net-zero emissions, with a target start year of 2023. The company is part of the Pharmaceuticals, Biotechnology, and Life Sciences sector, which is increasingly focusing on sustainability and reducing its carbon footprint. While specific emissions data is currently unavailable, GRAIL's proactive stance on climate commitments reflects a growing trend within the industry to prioritise environmental responsibility and sustainability.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GRAIL, Inc. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
